How I do it: Platelet support for refractory patients

Transfusion

Volumn 47, Issue 3, 2007, Pages 374-378

  Dzik, Sunny ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; AMPHOTERICIN; FIBRIN GLUE; HEPARIN; HLA A ANTIGEN; HLA B ANTIGEN; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MINOR HISTOCOMPATIBILITY ANTIGEN; RHESUS D ANTIBODY; THROMBOPOIETIN; VANCOMYCIN;

ALLOIMMUNIZATION; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD GROUP ABO SYSTEM; CANCER CHEMOTHERAPY; CLINICAL EVALUATION; DEMOGRAPHY; DIAGNOSTIC VALUE; DOCTOR PATIENT RELATION; ERYTHROCYTE TRANSFUSION; EXPECTATION; GRAFT RECIPIENT; HEMOSTASIS; HLA MATCHING; HLA SYSTEM; HUMAN; HYPOFIBRINOGENEMIA; IMMUNE DEFICIENCY; INTERPERSONAL COMMUNICATION; LEUKEMIA; PATIENT CARE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; SENSITIZATION; SUTURE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 33847062372     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01126.x     Document Type: Article

References (12)

1. Rebulla P. A mini-review of platelet refractoriness. Haematologica 2005;90:247-53.
2. Bock M, Muggenthaler KH, Schmidt U, Heim MU. Influence of antibiotics on post-transfusion platelet increment. Transfusion 1996;36:952-4.
3. Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105:4106-14.
4. Anasetti C, Doney KC, Storb RC, et al. Marrow transplantation for severe aplastic anemia: long term outcome in fifty 'untransfused' patients. Ann Intern Med 1986;104:461-6.
5. Dzik WH, Szczepiorkowski ZM. Leukocyte reduced products. In: Hillyer CD, Silberstein LE, Ness PM, Anderson KC, editors. Blood banking and transfusion medicine. Philadelphia: Churchill Livingstone; 2003. p. 219-40.
6. Dzik WH. First things first. In: Simon TL, Dzik WH, Snyder EL, Stowell CP, Strauss RG, editors. Rossi's principles of transfusion medicine. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 511-3.
7. Brecher ME, editor. Technical manual. 15th ed. Bethesda: American Association of Blood Banks; 2005. p. 362-6.
8. Rodey GE. HLA beyond tears. 2nd ed. Durango (CO): DeNovo, Inc.; 2000.
9. Kekomaki R. Use of HLA- and HPA-matched platelets in alloimmunized patients. Vox Sang 1998;74(Suppl 2):359-63.
10. Pappalardo PA, Secord AR, Quitevis P, Haimowitz MD, Goldfinger D. Platelet transfusion refractoriness associated with HPA-1a (Pl(A1)) alloantibody without co-existent HLA antibodies successfully treated with antigen-negative platelet transfusions. Transfusion 2001;41:984-7.
11. Dan ME, Schiffer CA. Strategies for managing refractoriness to platelet transfusions. Curr Hematol Rep 2003;2:158-64.
12. Heddle NM, Klama L, Kelton JG, et al. The use of anti-D to improve post-transfusion platelet response: a randomized trial. Br J Haematol 1995;89:163-8.